Effects of three fluoroquinolones on QT interval in healthy adults after single doses

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 4, 2003, Pages 292-303

  Noel, Gary J ^a   Natarajan, Jaya ^b   Chien, Shuchean ^b   Hunt, Thomas L ^b   Goodman, Daniel B ^b   Abels, Robert ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; POTASSIUM CHANNEL; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADULT; AGED; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HEART RATE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; QUINOLINES;

EID: 0037385205     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00009-2     Document Type: Article

References (26)

1. Owens RC. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21:310-9.
2. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin and azithromycin in rats. Antimicrob Agents Chemother 2000;44:2630-7.
3. Stahlman R, Schwabe R. Safety profile of grepafloxacin as compared with other fluoroquinolones. J Antimicrob Chemother 1997;40(Suppl A):83-92.
4. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998;104:22-6.
5. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointes probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350-1.
6. Samaha FF. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin [letter]. Am J Med 1999;107:528-9.
7. Demolis JL, Charrabsol A, Funck-Brentano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 1996;41:499-503.
8. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658-66.
9. Morganroth J, Talbot GH, Dorr MB, Johnson RD, Geary W, Manger D. Effects of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin Ther 1999;21:1171-81.
10. Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest 1999;115:983-6.
11. Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother 2000;45:557-9.
12. Stahlman R, Lode H. Safety overview. In: Andriole V, editor. The quinolones. 3rd ed. New York: Academic Press; 2000. p. 397-453.
13. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin. Pharmacotherapy 2001;21:1468-72.
14. + channel HERG. Mol Pharmacol 2001;59:122-6.
15. Avelox (moxifloxacin hydochloride). Physicians' desk reference. 56th ed. Montvale (NJ): Medical Economics; 2002. p. 879-83.
16. Kahn JB. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect [letter]. J Antimicrob Chemother 2000;46:847-8.
17. Anderson ME, Mazur A, Ang T, Roden DM. Potassium current channel antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001;296:806-8.
18. Levaquin tablets/injection. Physicians' desk reference. 56th ed. Montvale (NJ): Medical Economics; 2002. p. 2538.
19. Cipro (ciprofloxacin hydrochloride). Physicians' desk reference. 56th ed. Montvale (NJ): Medical Economics; 2002. p. 888.
20. Ratkowsky DA, Evans MA, Alldredge JR. Cross-over experiments: design, analysis, and application. New York: Marcel Dekker; 1992.
21. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96. London: The European Agency for the Evaluation of Medicinal Products; 1997.
22. Moss AJ. The QT interval and torsade de pointes. Drug Safety 1999;21(Suppl 1):5-10.
23. Barbey JT. Loratadine/nefazodone interaction [letter]. Clin Pharmacol Ther 2002;71:403.
24. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, et al. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 2001;69:96-103.
25. Iannini PB, Tillotson GS. Evaluating the risk of cardiac toxicity. Pharmacotherapy 2001;21:261-2.
26. Noel GJ, Abels R, Minton N, Natarajan J, Chien S. Effect of three fluoroquinolones on QTc intervals in healthy volunteers [abstract]. In: Proceedings of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; 2001 Dec 16-19; Chicago, Illinois. Washington: The Society; 2001.